Skip to main content

Table 2 Parasitological and clinical outcomes among patients treated with artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine after 28 days of follow-up, Yemen (2010–2013)

From: High efficacy of two artemisinin-based combinations: artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine for falciparum malaria in Yemen

Drug

Site

Year

n

PD3+

Without PCR-correction

With PCR-correction

Excluded/loss

LCF

LPF

ACPR

Cure rate (KM)

Excluded/loss

LCF

LPF

ACPR

Cure rate (KM)

n (%)

n (%)

n (%)

n (%)

n (%)

%

(95 % CI)

n (%)

n (%)

n (%)

n (%)

(%)

(95 % CI)

AS + SP

Al-Udayn

2010

85

0 (0)

2 (2.4)

0 (0)

0 (0)

83 (100)

100

(95.7–100)

2 (2.4)

0 (0)

0 (0)

83 (100)

100

(95.7–100)

AS + SP

Sharas

2010

93

0 (0)

11 (11.8)

0 (0)

0 (0)

82 (100)

100

(95.6–100)

11 (11.8)

0 (0)

0 (0)

82 (100)

100

(95.6–100)

AS + SP

Tur Bani Qa’is

2010

95

0 (0)

12 (13.7)

1 (1.2)

1(1.2)

81 (97.6)

97.6

(91.8–99.4)

14(14.7)

0 (0)

0 (0)

81 (100)

100

(95.9–100)

AS + SP

Al-Qaflah

2011

90

0 (0)

6 (6.7)

0 (0)

0 (0)

84 (100)

100

(95.7–100)

6 (6.7)

0 (0)

0 (0)

84 (100)

100

(95.7–100)

AS + SP

Bajil

2013

102

0 (0)

3 (2.9)

1 (1)

2 (2)

96 (97)

96

(89.6–98.5)

4 (3.9)

2 (2)

0 (0)

96 (98)

98

(92.2–99.5)

AL

Bajil

2009

80

0 (0)

6 (7.5)

0 (0)

0 (0)

74 (100)

100

(95.1–100)

6 (7.5)

0 (0)

0 (0)

74 (100)

100

(95.1–100)

AL

Jabal-Al-Sharq

2010

95

1 (1.1)

5 (5.3)

0 (0)

2 (2.2)

88 (97.8)

97.8

(92.2–99.7)

7 (7.4)

0 (0)

0 (0)

88 (100)

100

(95.9–100)

AL

Tur Bani Qa’is

2013

93

0 (0)

5 (5.4)

5 (5.7)

0 (0)

83 (94.3)

94.3

(87.2–98.1)

10 (10.8)

0 (0)

0 (0)

83 (100)

100

(95.7–100)

  1. LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, KM Kaplan–Meier, CI confidence interval, PD3+ positive blood film on day 3